Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
International Journal of Molecular Sciences · 27.03.2024 · 25 (7) · 3746
DOI: 10.3390/ijms25073746 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.03.2024. Verfasst von Kamila Kasprzak-Drozd und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland. Hauptthemen laut MEDLINE: Metabolic Diseases, Fatty Liver. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is influenced by a variety of factors, including environmental and genetic factors. The most significant outcome is the alteration of free fatty acid and triglyceride metabolism. Lipotoxicity, impaired autophagy, chronic inflammation, and oxidative stress, as well as coexisting insulin resistance, obesity, and changes in the composition of gut microbiota, are also considered crucial factors in the pathogenesis of MASLD. Resveratrol is a polyphenolic compound that belongs to the stilbene subgroup. This review summarises the available information on the therapeutic effects of resveratrol against MASLD. Resveratrol has demonstrated promising antisteatotic, antioxidant, and anti-inflammatory activities in liver cells in in vitro and animal studies. Resveratrol has been associated with inhibiting the NF-κB pathway, activating the SIRT-1 and AMPK pathways, normalizing the intestinal microbiome, and alleviating intestinal inflammation. However, clinical studies have yielded inconclusive results regarding the efficacy of resveratrol in alleviating hepatic steatosis or reducing any of the parameters found in MASLD in human patients. The lack of homogeneity between studies, low bioavailability of resveratrol, and population variability when compared to animal models could be the reasons for this.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland.
- Department of Pharmacology, Medical University of Lublin, Radziwiłłowska 11, 20-080 Lublin, Poland.
- Department of Conservative Dentistry with Endodontics, Medical University of Lublin, Chodźki 6, 20-093 Lublin, Poland.
- Department of Obstetrics and Pathology of Pregnancy, Medical University of Lublin, Staszica 16, 20-081 Lublin, Poland.
- Department of Thermal Technology and Food Process Engineering, University of Life Sciences in Lublin, Głęboka 31, 20-612 Lublin, Poland.
ORCID-Profile: Kamila Kasprzak-Drozd, Przemysław Niziński, Tomasz Oniszczuk, Anna Oniszczuk
Zitieren
APA
Kasprzak-Drozd, K., Niziński, P., Kasprzak, P., Kondracka, A., Oniszczuk, T., Rusinek, A., & Oniszczuk, A. (2024). Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?. International Journal of Molecular Sciences, 25(7), 3746. https://doi.org/10.3390/ijms25073746
Vancouver
Kasprzak-Drozd K, Niziński P, Kasprzak P, Kondracka A, Oniszczuk T, Rusinek A, et al. Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?. International Journal of Molecular Sciences. 2024;25(7):3746. doi:10.3390/ijms25073746
BibTeX
@article{KasprzakDrozd2024,
author = {Kasprzak-Drozd, Kamila and Niziński, Przemysław and Kasprzak, Paulina and Kondracka, Adrianna and Oniszczuk, Tomasz and Rusinek, Agata and Oniszczuk, Anna},
title = {Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {7},
pages = {3746},
doi = {10.3390/ijms25073746}
}
EUVIMED